Cucurbitacin IIa Alleviates Colitis via Promoting the Release of Host-Derived Extracellular Vesicles Encapsulating microRNA-30b-5p.

IF 4.1 2区医学 Q2 IMMUNOLOGY Journal of Inflammation Research Pub Date : 2025-01-31 eCollection Date: 2025-01-01 DOI:10.2147/JIR.S500722

Yinyin Zhao, Binyuan Jiang, Shengnan Zuo

{"title":"Cucurbitacin IIa Alleviates Colitis via Promoting the Release of Host-Derived Extracellular Vesicles Encapsulating microRNA-30b-5p.","authors":"Yinyin Zhao, Binyuan Jiang, Shengnan Zuo","doi":"10.2147/JIR.S500722","DOIUrl":null,"url":null,"abstract":"Purpose: Cucurbitacins have demonstrated anti-inflammatory effects and show promise for inflammatory bowel diseases. However, the underlying mechanisms by which cucurbitacins affect colitis remain largely unknown.Methods: In this study, we investigated the impact of cucurbitacin IIa on dextran sulfate sodium (DSS)-induced colitis in rats and the alterations in intestinal extracellular vesicles (EVs). EVs were isolated and characterized, followed by analysis of the small RNAs and proteins encapsulated within them using small RNA sequencing and proteomics, respectively.Results: Our results revealed that cucurbitacin IIa alleviated colitis symptoms in DSS-treated rats, along with changes in the morphology and composition of intestinal EVs. Notably, EVs from cucurbitacin IIa-treated rats also mitigated colitis symptoms in DSS-treated rats. Further analysis showed that cucurbitacin IIa modified the protein profiles and microRNA composition of EVs extracted from the feces of colitis rats. Specifically, microRNA-30b-5p, significantly increased by cucurbitacin IIa, was found to alleviate colitis symptoms in DSS-treated rats. In conclusion, cucurbitacin IIa appears to alleviate colitis by promoting the release of microRNA-30b-5p from host-derived extracellular vesicles.Conclusion: These findings enhance our understanding of cucurbitacin IIa's effects on intestinal health and offer potential new therapeutic targets for inflammatory bowel disease treatment.","PeriodicalId":16107,"journal":{"name":"Journal of Inflammation Research","volume":"18 ","pages":"1447-1458"},"PeriodicalIF":4.1000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11793106/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Inflammation Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JIR.S500722","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Cucurbitacins have demonstrated anti-inflammatory effects and show promise for inflammatory bowel diseases. However, the underlying mechanisms by which cucurbitacins affect colitis remain largely unknown.

Methods: In this study, we investigated the impact of cucurbitacin IIa on dextran sulfate sodium (DSS)-induced colitis in rats and the alterations in intestinal extracellular vesicles (EVs). EVs were isolated and characterized, followed by analysis of the small RNAs and proteins encapsulated within them using small RNA sequencing and proteomics, respectively.

Results: Our results revealed that cucurbitacin IIa alleviated colitis symptoms in DSS-treated rats, along with changes in the morphology and composition of intestinal EVs. Notably, EVs from cucurbitacin IIa-treated rats also mitigated colitis symptoms in DSS-treated rats. Further analysis showed that cucurbitacin IIa modified the protein profiles and microRNA composition of EVs extracted from the feces of colitis rats. Specifically, microRNA-30b-5p, significantly increased by cucurbitacin IIa, was found to alleviate colitis symptoms in DSS-treated rats. In conclusion, cucurbitacin IIa appears to alleviate colitis by promoting the release of microRNA-30b-5p from host-derived extracellular vesicles.

Conclusion: These findings enhance our understanding of cucurbitacin IIa's effects on intestinal health and offer potential new therapeutic targets for inflammatory bowel disease treatment.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

葫芦素IIa通过促进包裹microRNA-30b-5p的宿主源性细胞外囊泡的释放来缓解结肠炎。

目的：葫芦素已经证明了抗炎作用，并显示出对炎症性肠病的希望。然而，葫芦素影响结肠炎的潜在机制在很大程度上仍然未知。方法：本研究观察葫芦素IIa对葡聚糖硫酸钠（DSS）诱导大鼠结肠炎的影响及肠道细胞外囊泡（EVs）的改变。分离ev并对其进行表征，然后分别使用小RNA测序和蛋白质组学对其内封装的小RNA和蛋白质进行分析。结果：我们的研究结果显示，葫芦素IIa减轻了dss治疗大鼠的结肠炎症状，并改变了肠道EVs的形态和组成。值得注意的是，葫芦素iia治疗大鼠的ev也减轻了dss治疗大鼠的结肠炎症状。进一步分析表明，葫芦素IIa可以改变结肠炎大鼠粪便中提取的ev的蛋白谱和microRNA组成。具体来说，葫芦素IIa显著增加了microRNA-30b-5p，可以缓解dss治疗大鼠的结肠炎症状。总之，葫芦素IIa似乎通过促进宿主来源的细胞外囊泡释放microRNA-30b-5p来缓解结肠炎。结论：这些发现增强了我们对葫芦素IIa对肠道健康作用的认识，并为炎症性肠病的治疗提供了潜在的新靶点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

文献相关原料

公司名称

产品信息

阿拉丁

cucurbitacin IIa

来源期刊

Journal of Inflammation Research Immunology and Microbiology-Immunology

CiteScore

6.10

自引率

2.20%

发文量

658

审稿时长

16 weeks

期刊介绍： An international, peer-reviewed, open access, online journal that welcomes laboratory and clinical findings on the molecular basis, cell biology and pharmacology of inflammation.